MRI as outcome measure in facioscapulohumeral muscular dystrophy: 1-year follow-up of 45 patients

Journal of Neurology

Volumn 264, Issue 3, 2017, Pages 438-447

  Andersen, Grete ^a   Dahlqvist, Julia R ^a   Vissing, Christoffer R ^a   Heje, Karen ^a   Thomsen, Carsten ^a   Vissing, John ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Clinical trials; Facioscapulohumeral muscular dystrophy; MRI Dixon; Natural history studies; Observational study; Outcome measures

Indexed keywords

ADULT; AGED; ARTICLE; BACK; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DYNAMOMETRY; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; FEMALE; FOLLOW UP; FUNCTION TEST; GASTROCNEMIUS MUSCLE; HIP; HUMAN; LONGITUDINAL STUDY; MALE; MUSCLE STRENGTH; NECK; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PARASPINAL MUSCLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; THIGH MUSCLE; YOUNG ADULT; ADIPOSE TISSUE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC IMAGING; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX; SKELETAL MUSCLE;

ADIPOSE TISSUE; ADULT; AGED; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUSCLE STRENGTH; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 85006820980     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-016-8361-3     Document Type: Article

References (29)

1. Tawil R, Kissel JT, Heatwole C et al (2015) Evidence-based guideline summary: evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. Neurology 85:357–364. doi:10.1212/WNL.0000000000001783
2. Tawil R, van der Maarel SM, Tapscott SJ (2014) Facioscapulohumeral dystrophy: the path to consensus on pathophysiology. Skelet Muscle 4:12. doi:10.1186/2044-5040-4-12
3. Dahlqvist JR, Vissing CR, Thomsen C, Vissing J (2014) Severe paraspinal muscle involvement in facioscapulohumeral muscular dystrophy. Neurology 83:1178–1183. doi:10.1212/WNL.0000000000000828
4. Sookhoo S, Mackinnon I, Bushby K et al (2007) MRI for the demonstration of subclinical muscle involvement in muscular dystrophy. Clin Radiol 62:160–165. doi:10.1016/j.crad.2006.08.012
5. Dixon WT (1984) Simple proton spectroscopic imaging. Radiology 153:189–194. doi:10.1148/radiology.153.1.6089263
6. Ma J (2008) Dixon techniques for water and fat imaging. J Magn Reson Imaging JMRI 28:543–558. doi:10.1002/jmri.21492
7. Willis TA, Hollingsworth KG, Coombs A et al (2013) Quantitative muscle MRI as an assessment tool for monitoring disease progression in LGMD2I: a multicentre longitudinal study. PLoS One 8:e70993. doi:10.1371/journal.pone.0070993
8. Lamperti C, Fabbri G, Vercelli L et al (2010) A standardized clinical evaluation of patients affected by facioscapulohumeral muscular dystrophy: the FSHD clinical score. Muscle Nerve 42:213–217. doi:10.1002/mus.21671
9. Andersen G, Prahm KP, Dahlqvist JR et al (2015) Aerobic training and postexercise protein in facioscapulohumeral muscular dystrophy: RCT study. Neurology 85:396–403. doi:10.1212/WNL.0000000000001808
10. van der Kooi EL, Vogels OJM, van Asseldonk RJGP et al (2004) Strength training and albuterol in facioscapulohumeral muscular dystrophy. Neurology 63:702–708
11. Wagner KR, Fleckenstein JL, Amato AA et al (2008) A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 63:561–571. doi:10.1002/ana.21338
12. Kissel JT, McDermott MP, Mendell JR et al (2001) Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy. Neurology 57:1434–1440
13. Statland JM, McDermott MP, Heatwole C et al (2013) Reevaluating measures of disease progression in facioscapulohumeral muscular dystrophy. Neuromuscul Disord NMD 23:306–312. doi:10.1016/j.nmd.2013.01.008
14. Eichinger K, Heatwole C, Heininger S et al (2016) Validity of the six minute walk test in facioscapulohumeral muscular dystrophy. Muscle Nerve. doi:10.1002/mus.25251
15. Kan HE, Scheenen TWJ, Wohlgemuth M et al (2009) Quantitative MR imaging of individual muscle involvement in facioscapulohumeral muscular dystrophy. Neuromuscul Disord 19:357–362. doi:10.1016/j.nmd.2009.02.009
16. Fischmann A, Hafner P, Fasler S et al (2012) Quantitative MRI can detect subclinical disease progression in muscular dystrophy. J Neurol 259:1648–1654. doi:10.1007/s00415-011-6393-2
17. Regula JU, Jestaedt L, Jende F et al (2015) Clinical muscle testing compared with whole-body magnetic resonance imaging in facioscapulohumeral muscular dystrophy. Clin Neuroradiol. doi:10.1007/s00062-015-0386-y
18. Leung DG, Carrino JA, Wagner KR, Jacobs MA (2015) Whole-body magnetic resonance imaging evaluation of facioscapulohumeral muscular dystrophy. Muscle Nerve 52:512–520. doi:10.1002/mus.24569
19. Janssen B, Voet N, Geurts A et al (2016) Quantitative MRI reveals decelerated fatty infiltration in muscles of active FSHD patients. Neurology. doi:10.1212/WNL.0000000000002640
20. Tasca G, Monforte M, Iannaccone E et al (2014) upper girdle imaging in facioscapulohumeral muscular dystrophy. PLoS One. doi:10.1371/journal.pone.0100292
21. Friedman SD, Poliachik SL, Otto RK et al (2014) Longitudinal features of STIR bright signal in FSHD. Muscle Nerve 49:257–260. doi:10.1002/mus.23911
22. Janssen BH, Voet NBM, Nabuurs CI et al (2014) Distinct disease phases in muscles of facioscapulohumeral dystrophy patients identified by MR detected fat infiltration. PLoS One. doi:10.1371/journal.pone.0085416
23. Lareau-Trudel E, Le Troter A, Ghattas B et al (2015) Muscle quantitative mr imaging and clustering analysis in patients with facioscapulohumeral muscular dystrophy type 1. PLoS One. doi:10.1371/journal.pone.0132717
24. Frisullo G, Frusciante R, Nociti V et al (2011) CD8+ T cells in facioscapulohumeral muscular dystrophy patients with inflammatory features at muscle MRI. J Clin Immunol 31:155–166. doi:10.1007/s10875-010-9474-6
25. Tasca G, Pescatori M, Monforte M et al (2012) Different molecular signatures in magnetic resonance imaging-staged facioscapulohumeral muscular dystrophy muscles. PLoS One. doi:10.1371/journal.pone.0038779
26. Tasca G, Monforte M, Ottaviani P et al (2016) Magnetic resonance imaging in a large cohort of facioscapulohumeral muscular dystrophy patients: pattern refinement and implications for clinical trials. Ann Neurol. doi:10.1002/ana.24640
27. Morrow JM, Sinclair CDJ, Fischmann A et al (2016) MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study. Lancet Neurol 15:65–77. doi:10.1016/S1474-4422(15)00242-2
28. Dahlqvist JR, Vissing CR, Hedermann G et al (2016) Fat replacement of paraspinal muscles with aging in healthy adults. Med Sci Sports Exerc. doi:10.1249/MSS.0000000000001119
29. Baum T, Inhuber S, Dieckmeyer M et al (2016) Association of quadriceps muscle fat with isometric strength measurements in healthy males using chemical shift encoding-based water-fat magnetic resonance imaging. J Comput Assist Tomogr 40:447–451. doi:10.1097/RCT.0000000000000374